Hynic-TOC

Catalog No: 20658

CAS Number: 257943-19-4

Purity: 98% Min.

Hynic-TOC is a ligand for making 99mTc-Hynic-TOC as an imaging agent in the diagnostic of neuroendocrine tumor.

For research use only. We do not sell to patients.

Chemical Information

Name	Hynic-TOC
Iupac Chemical Name	(4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-10-(4-aminobutyl)-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-19-((R)-2-((E)-6-hydrazineylidene-1,6-dihydropyridine-3-carboxamido)-3-phenylpropanamido)-16-(4-hydroxybenzyl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide
Synonyms	HYNIC-Tyr3-octreotide; Hynic-TOC; HynicTOC; Hynic TOC; Hydrazinonicotinyl-Tyr3-octreotide
Molecular Formula	C55H71N13O12S2
Molecular Weight	1170.36
Smile	O=C([C@@H](NC([C@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@H](CO)[C@H](O)C)=O)NC([C@H](NC(C(C=C/2)=CNC2=N\N)=O)CC3=CC=CC=C3)=O)=O)CC4=CC=C(C=C4)O)N[C@@H]1CC5=CNC6=CC=CC=C56
InChiKey	WJBPMDZACHSXSD-HLAGHTPDSA-N
InChi	InChI=1S/C55H71N13O12S2/c1-30(70)43(27-69)64-54(79)45-29-82-81-28-44(65-51(76)40(22-32-10-4-3-5-11-32)61-48(73)34-17-20-46(68-57)59-25-34)53(78)62-41(23-33-15-18-36(72)19-16-33)50(75)63-42(24-35-26-58-38-13-7-6-12-37(35)38)52(77)60-39(14-8-9-21-56)49(74)67-47(31(2)71)55(80)66-45/h3-7,10-13,15-20,25-26,30-31,39-45,47,58,69-72H,8-9,14,21-24,27-29,56-57H2,1-2H3,(H,59,68)(H,60,77)(H,61,73)(H,62,78)(H,63,75)(H,64,79)(H,65,76)(H,66,80)(H,67,74)/t30-,31-,39+,40-,41+,42-,43-,44+,45+,47+/m1/s1
CAS Number	257943-19-4
Related CAS

Ordering Information

Packaging	Price	Availability	Purity	Shipping Time
Bulk		Enquiry	Enquiry	Enquiry

Request Bulk Quote Download MSDS Tel : +86-177 0271 9238 Email : sales@sun-shinechem.com

Formulation	Solid powder
Purity	98% Min.
Storage	Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility	Soluble in DMSO
Handling
Shipping Condition	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
HS Code

Coming soon.

Targets
Mechanism
Cell study
Animal study
Clinical study

1: Briganti V, Cuccurullo V, Berti V, Di Stasio GD, Linguanti F, Mungai F, Mansi
L. 99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors
of the Lung (and in other Malignant and Benign Pulmonary Diseases). Curr
Radiopharm. 2020;13(3):166-176. doi: 10.2174/1874471013666191230143610. PMID:
31886756; PMCID: PMC8193811.

2: Garai I, Barna S, Nagy G, Forgacs A. Limitations and pitfalls of 99mTc-
EDDA/HYNIC-TOC (Tektrotyd) scintigraphy. Nucl Med Rev Cent East Eur.
2016;19(2):93-8. doi: 10.5603/NMR.2016.0019. PMID: 27479887.

3: Shi X, Jing H, Li F, Zhao Y, Wang Z, Huo L. 99mTc-HYNIC-TOC in the Evaluation
of Recurrent Tumor-Induced Osteomalacia. Clin Nucl Med. 2019 Mar;44(3):209-213.
doi: 10.1097/RLU.0000000000002458. PMID: 30672760.

4: Li B, Duan L, Li X, Shi J, Li H, Liu H, Cheng X, Wu X, Gao Y. Diagnostic
accuracy of 99mTc-HYNIC-TOC SPECT/CT for detecting osteomalacia-
associated tumors. Front Oncol. 2023 Jul 24;13:1228575. doi:
10.3389/fonc.2023.1228575. PMID: 37554164; PMCID: PMC10405922.

5: Liepe K, Becker A. 99mTc-Hynic-TOC imaging in the diagnostic of
neuroendocrine tumors. World J Nucl Med. 2018 Jul-Sep;17(3):151-156. doi:
10.4103/wjnm.WJNM_41_17. PMID: 30034278; PMCID: PMC6034543.

6: Chaib S, Hallouard F, Chennell P, Darcissac C, Morelec I, Rioufol C, Sautou
V, Fraysse M. Compatibility of [99mTc]Tc-EDDA/HYNIC-TOC and [68Ga] Ga-DOTA-TOC
in a syringe for intravenous administration. Nucl Med Commun. 2020
Jan;41(1):11-17. doi: 10.1097/MNM.0000000000001108. PMID: 31764593.

7: Hou G, Jiang Y, Li F, Zhu Z, Jing H. Site-based performance of 131I-MIBG
imaging and 99mTc-HYNIC-TOC scintigraphy in the detection of nonmetastatic
extra-adrenal paraganglioma. Nucl Med Commun. 2022 Jan 1;43(1):32-41. doi:
10.1097/MNM.0000000000001490. PMID: 34570039; PMCID: PMC8654250.

8: Gherghe M, Lazăr AM, Stanciu AE, Mutuleanu MD, Sterea MC, Petroiu C, Galeș
LN. The New Radiolabeled Peptide 99mTcEDDA/HYNIC-TOC: Is It a
Feasible Choice for Diagnosing Gastroenteropancreatic NETs? Cancers (Basel).
2022 May 31;14(11):2725. doi: 10.3390/cancers14112725. PMID: 35681704; PMCID:
PMC9179571.

9: Sager S, Kabasakal L, Halac M, Maecke H, Uslu L, Önsel Ç, Kanmaz B.
Comparison of 99mTc-HYNIC-TOC and HYNIC-TATE octreotide scintigraphy with FDG
PET and 99mTc-MIBI in local recurrent or distant metastatic thyroid cancers.
Clin Nucl Med. 2013 May;38(5):321-5. doi: 10.1097/RLU.0b013e3182868062. PMID:
23531772.

10: Boutsikou E, Porpodis K, Chatzipavlidou V, Hardavella G, Gerasimou G, Domvri
K, Papadopoulos N, Avramidou V, Spyratos D, Kontakiotis T, Zarogoulidis K.
Predictive Value of 99MTC-hynic-toc Scintigraphy in Lung Neuroendocrine Tumor
Diagnosis. Technol Cancer Res Treat. 2019 Jan 1;18:1533033819842586. doi:
10.1177/1533033819842586. PMID: 31079574; PMCID: PMC6535698.

Chemical Structure

Hynic-TOC

Chemical Information

Ordering Information

Chemical Structure

Quick Order

Products